These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36764576)

  • 21. Benefits of Strategic Small-Scale Targeted Screening.
    Sharlow ER
    Assay Drug Dev Technol; 2016 Aug; 14(6):329-32. PubMed ID: 27341343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening methods for influenza antiviral drug discovery.
    Atkins C; Evans CW; White EL; Noah JW
    Expert Opin Drug Discov; 2012 May; 7(5):429-38. PubMed ID: 22435452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational drug repositioning: from data to therapeutics.
    Hurle MR; Yang L; Xie Q; Rajpal DK; Sanseau P; Agarwal P
    Clin Pharmacol Ther; 2013 Apr; 93(4):335-41. PubMed ID: 23443757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repurposing old drugs to fight multidrug resistant cancers.
    Dinić J; Efferth T; García-Sosa AT; Grahovac J; Padrón JM; Pajeva I; Rizzolio F; Saponara S; Spengler G; Tsakovska I
    Drug Resist Updat; 2020 Sep; 52():100713. PubMed ID: 32615525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of HTS in drug discovery at the University of Michigan.
    Larsen MJ; Larsen SD; Fribley A; Grembecka J; Homan K; Mapp A; Haak A; Nikolovska-Coleska Z; Stuckey JA; Sun D; Sherman DH
    Comb Chem High Throughput Screen; 2014 Mar; 17(3):210-30. PubMed ID: 24409957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug discovery for human African trypanosomiasis: identification of novel scaffolds by the newly developed HTS SYBR Green assay for Trypanosoma brucei.
    Faria J; Moraes CB; Song R; Pascoalino BS; Lee N; Siqueira-Neto JL; Cruz DJ; Parkinson T; Ioset JR; Cordeiro-da-Silva A; Freitas-Junior LH
    J Biomol Screen; 2015 Jan; 20(1):70-81. PubMed ID: 25342146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Research Techniques Made Simple: An Introduction to Drug Discovery for Dermatology.
    Bell M; Webster L; Woodland A
    J Invest Dermatol; 2019 Nov; 139(11):2252-2257.e1. PubMed ID: 31648685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A rapid and affordable screening platform for membrane protein trafficking.
    Snyder JC; Pack TF; Rochelle LK; Chakraborty SK; Zhang M; Eaton AW; Bai Y; Ernst LA; Barak LS; Waggoner AS; Caron MG
    BMC Biol; 2015 Dec; 13():107. PubMed ID: 26678094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis.
    Scannell JW; Bosley J
    PLoS One; 2016; 11(2):e0147215. PubMed ID: 26863229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementation and Use of State-of-the-Art, Cell-Based In Vitro Assays.
    Langer G
    Handb Exp Pharmacol; 2016; 232():171-90. PubMed ID: 26424721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-throughput drug repositioning for the discovery of new treatments for Chagas disease.
    Bellera CL; Sbaraglini ML; Balcazar DE; Fraccaroli L; Vanrell MC; Casassa AF; Labriola CA; Romano PS; Carrillo C; Talevi A
    Mini Rev Med Chem; 2015; 15(3):182-93. PubMed ID: 25769967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The University of Kansas High-Throughput Screening Laboratory. Part II: enabling collaborative drug-discovery partnerships through cutting-edge screening technology.
    McDonald PR; Roy A; Chaguturu R
    Future Med Chem; 2011 Jul; 3(9):1101-10. PubMed ID: 21806374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico repositioning of approved drugs for rare and neglected diseases.
    Ekins S; Williams AJ; Krasowski MD; Freundlich JS
    Drug Discov Today; 2011 Apr; 16(7-8):298-310. PubMed ID: 21376136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.
    Cheng F; Hong H; Yang S; Wei Y
    Brief Bioinform; 2017 Jul; 18(4):682-697. PubMed ID: 27296652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug repositioning in cancer: The current situation in Japan.
    Masuda T; Tsuruda Y; Matsumoto Y; Uchida H; Nakayama KI; Mimori K
    Cancer Sci; 2020 Apr; 111(4):1039-1046. PubMed ID: 31957175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The University of New Mexico Center for Molecular Discovery.
    Edwards BS; Gouveia K; Oprea TI; Sklar LA
    Comb Chem High Throughput Screen; 2014 Mar; 17(3):256-65. PubMed ID: 24409953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using iterative cluster merging with improved gap statistics to perform online phenotype discovery in the context of high-throughput RNAi screens.
    Yin Z; Zhou X; Bakal C; Li F; Sun Y; Perrimon N; Wong ST
    BMC Bioinformatics; 2008 Jun; 9():264. PubMed ID: 18534020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.
    Nagaraj AB; Wang QQ; Joseph P; Zheng C; Chen Y; Kovalenko O; Singh S; Armstrong A; Resnick K; Zanotti K; Waggoner S; Xu R; DiFeo A
    Oncogene; 2018 Jan; 37(3):403-414. PubMed ID: 28967908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of chemogenomic library screening in drug discovery.
    Jones LH; Bunnage ME
    Nat Rev Drug Discov; 2017 Apr; 16(4):285-296. PubMed ID: 28104905
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.